Matt Miksic
Stock Analyst at Barclays
(1.65)
# 1429
Out of 5,347 analysts
267
Total ratings
57.14%
Success rate
6.40%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
LIVN LivaNova | Maintains: Equal-Weight | 56 55 | 43.23 | 27.23% | 7 | May 8, 2025 | |
OBIO Orchestra BioMed Hld... | Maintains: Overweight | 16 12 | 2.86 | 319.58% | 2 | May 5, 2025 | |
DXCM DexCom | Maintains: Equal-Weight | 90 93 | 85.8 | 8.39% | 6 | May 5, 2025 | |
PODD Insulet | Maintains: Equal-Weight | 234 266 | 325.07 | -18.17% | 8 | Apr 30, 2025 | |
INMD InMode | Maintains: Overweight | 29 24 | 14.66 | 63.71% | 13 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 118 125 | 105.19 | 18.83% | 14 | Apr 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 684 635 | 552.31 | 14.97% | 7 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 166 165 | 155.02 | 6.44% | 12 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 158 159 | 133.57 | 19.04% | 26 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 39 41 | 30.5 | 34.43% | 17 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 60 53 | 19.83 | 167.27% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 100 103 | 59.2 | 73.99% | 14 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 88 90 | 78.2 | 15.09% | 23 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 118 112 | 92.16 | 21.53% | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 418 443 | 382.59 | 15.79% | 21 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 20 21 | 12.42 | 69.08% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 22 | 4.25 | 417.65% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 105 109 | 82.97 | 31.37% | 15 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 13 16 | 9.15 | 74.86% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 17 18 | 11.48 | 56.79% | 4 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 56 58 | n/a | n/a | 6 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 15 | n/a | n/a | 1 | Dec 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 96 | 85.95 | 11.69% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 100 | 69.96 | 42.94% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 722 418 | 180.93 | 131.03% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 31 28 | 12.23 | 128.95% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 68 67 | 15.95 | 320.06% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 11 4 | n/a | n/a | 4 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 480 | 7.76 | 6085.57% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 84 87 | 12.66 | 587.2% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 24 25 | 2.73 | 815.75% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 200 160 | n/a | n/a | 2 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 26 24 | n/a | n/a | 1 | Oct 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sell | 9 | 6.44 | 39.75% | 1 | Dec 12, 2016 |